A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial).
Fiche publication
Date publication
octobre 2021
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LEROUX Agnès, Pr MERLIN Jean-Louis, Dr RIOS Maria
Tous les auteurs :
Campone M, Bachelot T, Treilleux I, Pistilli B, Salleron J, Seegers V, Arnedos M, Loussouarn D, Wang Q, Vanlemmens L, Jimenez M, Rios M, Diéras V, Leroux A, Paintaud G, Rezai K, André F, Lion M, Merlin JL
Lien Pubmed
Résumé
Resistance to trastuzumab in breast cancer is an ongoing challenge. Clinical and biological effects of co-targeting HER2 and mammalian target of rapamycin (mTOR) in patients with HER2-positive early operable breast cancer via the addition of everolimus to preoperative trastuzumab were evaluated in a phase II randomised study.
Mots clés
Biomarker, Everolimus, HER2+ breast cancer, PI3K/AKT/mTOR, Trastuzumab
Référence
Eur J Cancer. 2021 Oct 19;158:169-180